3,400+employees

(as of January 29, 2020)

Trials in 35countries and regions

10 officeson 4 continents

The BeiGene StoryA global biopharmaceutical innovator focused on improving treatment outcomes and patient access

BeiGene is a fully-integrated biopharmaceutical

company co-founded in 2010 by John Oyler, an

American entrepreneur, and Dr. Xiaodong Wang,

one of the youngest ever U.S. Academy of Science

members and Director of China’s National Institute

of Biological Sciences (NIBS) in Beijing. The two set

out to build a unique company that was globally

focused from its inception.

BeiGene (NASDAQ: BGNE; HKEX 06160) focuses on

developing novel cancer therapies where there is

global unmet need.

Our broad product portfolio and pipeline include:

• 3 wholly owned late-stage oncology candidates,

including one approved in the U.S. and one

approved in China

• 27 Phase 3 or potentially registration-enabling

trials ongoing, 60+ studies in total

• 32 clinical or commercial stage assets including

seven internally developed and 25 in-licensed

BeiGene has built a strong innovative pipeline of

clinical drug candidates through internal discovery

and collaborations.

Transformative Collaboration with Amgen

This global strategic oncology collaboration expands

access to important oncology medicines for patients

in China and around the globe with:

• BeiGene commercializing three Amgen oncology

products in China — XGEVA® (denosumab),

KYPROLIS™ (carfilzomib), and BLINCYTO®

(blinatumomab)

• Companies jointly developing 20 Amgen

oncology pipeline assets globally, with BeiGene

leading development in China

• Amgen investing $2.8B for a 20.5%

stake in BeiGene

1Abbreviated pipeline as of January 9, 2020. For full pipeline, visit beigene.com/science-and-product-portfolio/pipeline

• Investigational KRASG12C small molecule inhibitor • In-licensed from Amgen, rights in China

• Investigational humanized lgG1-variant monoclonal antibody against TIM-3• Currently being investigated in combination with tislelizumab in solid tumors

• Investigational spectrum-selective kinase inhibitor of receptor tyrosine kinases, including RET, TAM family receptors (TYRO3, Axl, MER) and split family receptors (VEGFR2, KIT)

• Currently being investigated in combination with tislelizumab in solid tumors• In-licensed from Mirati Therapeutics, rights in Asia ex-Japan, AU, NZ

• Investigational TIGIT monoclonal antibody • Currently being investigated as in combination with tislelizumab in solid tumors

• Investigational small molecule Bcl-2 inhibitor • Currently being investigated as a monotherapy and in combination with zanubrutinib in

hematologic malignancies

• Investigational HER2-targeted bispecific antibody • Currently being investigated in combination with tislelizumab in solid tumors • In-licensed from Zymeworks, rights in Asia ex-Japan, AU, NZ

• Investigational HER2-targeted bispecific antibody drug conjugate (ADC)• In-licensed from Zymeworks, rights in Asia ex-Japan, AU, NZ

BGB-A425

BGB-A1217

BGB-11417

Sitravatinib

ZW25

ZW49

AMG 510

• Potent second generation small molecule inhibitor of Bruton’s tyrosine kinase • Currently being investigated as a monotherapy and in combination with other

therapies in multiple hematologic malignancies

• Investigational novel small molecule inhibitor with RAF monomer and dimer inhibition activities • Currently being investigated as a monotherapy and in combination with mirdametinib (MEK

inhibitor from SpringWorks Therapeutics) in solid tumors

• Investigational humanized monoclonal antibody against the immune checkpoint receptor ligand PD-L1

• Currently being investigated as a monotherapy and in combination with tislelizumab in solid tumors

• Investigational small molecule inhibitor of PARP1 and PARP2• Currently being investigated as a monotherapy and in combination with other therapies

in multiple solid tumors

• Humanized IgG4 anti-PD-1 monoclonal antibody • Currently being investigated as a monotherapy and in combination with other therapies

in multiple solid tumors and hematologic malignancies

Zanubrutinib

Tislelizumab

Pamiparib

Lifirafenib

BGB-A333

BEIGENE’S SELECTED INVESTIGATIONAL PIPELINE1

• China NMPA approvals in R/R multiple myeloma and multiple myeloma• In-licensed from Celgene (a Bristol-Myers Squibb) company, rights in China

• China NMPA approval in breast cancer • In-licensed from Celgene (a Bristol-Myers Squibb) company, rights in China

• China NMPA approvals in myelodysplastic syndrome, acute myeloid leukemia, chronic myelomonocytic leukemia

• In-licensed from Celgene (a Bristol-Myers Squibb) company, rights in China

REVLIMID® (lenalidomide)

VIDAZA® (azacitidine)

ABRAXANE® (albumin-bound paclitaxel)

BRUKINSA™ (zanubrutinib)

Tislelizumab

• U.S. FDA accelerated approval in November 2019 for relapsed/ refractory (R/R) mantle cell lymphoma

• China NMPA approval in giant cell tumor of bone• In-licensed from Amgen, rights in China

• China NMPA approval in R/R classical Hodgkin’s lymphoma

XGEVA® (denosumab)

BEIGENE’S COMMERCIAL PRODUCT PORTFOLIO

BeiGene’s commitment is to never compromise

on the safety, compliance, or quality of our

products, our research, or our services. We are

focused on serving patients by delivering quality

drug products that consistently meet or exceed all

customer and regulatory requirements. Each

BeiGene employee and partner is responsible for

achieving our objectives and for looking at any

opportunity where we can improve upon our high

standards of performance.

BeiGene conducts its clinical trials in accordance

with the regulatory requirements of the U.S. Food

and Drug Administration (FDA), the European

Medicines Agency (EMA), and the China National

Medical Products Administration (NMPA), as

applicable. Likewise, BeiGene’s own state-of-the-art

manufacturing facilities, located in China, are fully

compliant with Good Manufacturing Practice (GMP)

requirements of the U.S., European and Chinese

authorities and subject to inspection and approval

by these authorities. It has also contracted with

leading American and German manufacturers for

production of its drug candidates.

Our Commitment

BeiGene employees are dedicated to translating groundbreaking science into quality innovative cancer therapies.

With a global headcount of over 3,400 employees, more than 1,000 are devoted to global clinical development and approximately 1,000 are in commercial operation.

John V. OylerChairman, Founder & CEOBioDuro, Galenea, Telephia, Genta, McKinsey & Company

Xiaodong Wang, Ph.D.Founder & Chairman SABNIBS: National Institute of Biological Sciences in Beijing, UT Southwestern Medical Center, Howard Hughes Medical Institute, National Academy of Sciences

Yong (Ben) Ben, M.D.CMO, Immuno-OncologyBioAtla, AstraZeneca

Josh NeimanHead of U.S. Commercial Flatiron Health, Onyx Pharmaceuticals, Genentech

Jane Huang, M.D.CMO, HematologyAcerta, Genentech

Todd Yancey, M.D.SVP, Global Medical Affairs & New Market DevelopmentBioMarin, Clovis Oncology, Medivation, Onyx Pharmaceuticals

Xiaobin Wu, Ph.D.GM of China & President Pfizer, Wyeth, Bayer

Eric Hedrick, M.D.Chief AdvisorGenentech, Pharmacyclics, Epizyme

Guillaume Vignon, Ph.D.SVP, Business DevelopmentMerck KGaA

Lai Wang, Ph.D.SVP, Head of Global Research, Clinical Operation, Biometrics & APAC Clinical DevelopmentJoyant Pharmaceuticals, Howard Hughes Medical Institute

Meet Members of Our Leadership Team

www.beigene.com

@BeiGeneUSA

Our employees look forward to connecting with youto provide additional insight into BeiGene.

Contact us at: 888-123-4455 or info@beigene.com

©2020 BeiGene, Inc.